{"id":"NCT02364947","sponsor":"Otsuka Pharmaceutical Co., Ltd.","briefTitle":"A Multicenter, Randomized, Double-blind, Placebo-controlled, 3-parallel-group Comparison Trial to Investigate the Effect of Nalmefene on Alcohol Consumption Reduction in Patients With Alcohol Dependence (Phase 3 Trial)","officialTitle":"A Multicenter, Randomized, Double-blind, Placebo-controlled, 3-parallel-group Comparison Trial to Investigate the Effect of Nalmefene on Alcohol Consumption Reduction in Patients With Alcohol Dependence (Phase 3 Trial)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-02-09","primaryCompletion":"2016-07-30","completion":"2016-07-30","firstPosted":"2015-02-18","resultsPosted":"2019-09-30","lastUpdate":"2019-09-30"},"enrollment":678,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Alcohol Dependence"],"interventions":[{"type":"DRUG","name":"Nalmefene hydrochloride","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Nalmefene hydrochloride 10 mg","type":"EXPERIMENTAL"},{"label":"Nalmefene hydrochloride 20 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The efficacy, safety, and dose-response of nalmefene hydrochloride at 10 mg and 20 mg in patients with alcohol dependence will be evaluated in a multicenter, randomized, double-blind, placebo-controlled, 3-parallel-group comparative trial. The superiority of nalmefene hydrochloride at 20 mg to placebo will be verified in terms of reduction of alcohol consumption.","primaryOutcome":{"measure":"Change in the Number of Heavy Drinking Days (HDDs) From Baseline at Week 12","timeFrame":"Week 12","effectByArm":[{"arm":"Nalmefene Hydrochloride 20 mg","deltaMin":-12.25,"sd":0.64},{"arm":"Nalmefene Hydrochloride 10 mg","deltaMin":-12.09,"sd":0.74},{"arm":"Placebo","deltaMin":-7.91,"sd":0.61}],"pValues":[{"comp":"OG000 vs OG002","p":"0.0001"},{"comp":"OG001 vs OG002","p":"0.0001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":7,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":248},"commonTop":["Nasopharyngitis","Nausea","Dizziness","Somnolence","Headache"]}}